Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company specializing in developing next-generation therapeutics for central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Their lead product candidate, RP5063, is in Phase III clinical trials for schizophrenia treatment and has completed Phase I trials for various other conditions. Additionally, the company is developing RP1208 for depression and obesity treatment. By advancing these innovative therapies through clinical trials and potential commercialization, Reviva Pharmaceuticals aims to generate revenue from the sale of these therapeutics to address unmet medical needs in multiple disease areas.

Products

• RP5063 for schizophrenia and other conditions

• RP1208 for depression and obesity